Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes ...

US Senator Elizabeth Warren has asked the Federal Trade Commission (FTC) to look into a $16.5 billion deal that would give Novo Nordisk control of manufacturing facilities currently operated by ...

As a result, to meet growing demand, Novo Nordisk acquired Catalent for $16.5 billion in 2024. However, let's return to the discussion of how Novo Nordisk's EPS has changed and what to expect in 2025.

Moreover, free cash flow turned negative at minus DKK14.7 billion, largely due to heavy capital expenditures and the Catalent acquisition. Despite these challenges, Novo Nordisk remains well ...

We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to ...

Novo Nordisk also reinforced its leadership in the GLP-1 market, maintaining its dominant position with nearly two-thirds of all GLP-1 patients using its treatments. A key milestone for the company ...

Novo Nordisk NVO shares have lost 21% in the past ... primarily driven by increased sales of Wegovy and Ozempic. The closing of the Catalent deal in December last year is also expected to help ...

Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also ...

It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...

Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired ...